VRCI.L
Price:
$3.25
Market Cap:
$10.16M
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
2020-11-03
Stock Exchange
LSE
Ticker
VRCI.L
According to Verici Dx plc’s latest financial reports and current stock price. The company's current Enterprise Value is 3.61M. This represents a change of -78.94% compared to the average of 17.13M of the last 4 quarters.
The mean historical Enterprise Value of Verici Dx plc over the last ten years is 44.30M. The current 3.61M Enterprise Value has changed 714.40% with respect to the historical average. Over the past ten years (40 quarters), VRCI.L's Enterprise Value was at its highest in in the June 2021 quarter at 119.72M. The Enterprise Value was at its lowest in in the June 2024 quarter at 12.60M.
Average
44.30M
Median
35.32M
Minimum
15.23M
Maximum
91.32M
Discovering the peaks and valleys of Verici Dx plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 76.95%
Maximum Annual Enterprise Value = 91.32M
Minimum Annual Increase = -83.33%
Minimum Annual Enterprise Value = 15.23M
Year | Enterprise Value | Change |
---|---|---|
2023 | 19.03M | 25.00% |
2022 | 15.23M | -83.33% |
2021 | 91.32M | 76.95% |
The current Enterprise Value of Verici Dx plc (VRCI.L) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
41.86M
5-year avg
44.30M
10-year avg
44.30M
Verici Dx plc’s Enterprise Value is less than Renalytix Plc (26.40M), greater than Trellus Health plc (-4192075.65), less than EKF Diagnostics Holdings plc (87.97M), less than Polarean Imaging plc (9.22M), greater than Destiny Pharma plc (-3509485.00),
Company | Enterprise Value | Market cap |
---|---|---|
26.40M | $28.15M | |
-4192075.65 | $2.99M | |
87.97M | $97.55M | |
9.22M | $11.77M | |
-3509485.00 | $2.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verici Dx plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Verici Dx plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Verici Dx plc's Enterprise Value?
What is the highest Enterprise Value for Verici Dx plc (VRCI.L)?
What is the 3-year average Enterprise Value for Verici Dx plc (VRCI.L)?
What is the 5-year average Enterprise Value for Verici Dx plc (VRCI.L)?
How does the current Enterprise Value for Verici Dx plc (VRCI.L) compare to its historical average?